MedicinefromArs Technica4 hours agoClinical trial shows gene editing works for -Thalassaemia, tooAn improved gene editing system reactivates a fetal hemoglobin gene to treat β-Thalassaemia, building on CRISPR's success with sickle-cell anemia.